

AMENDMENTS TO THE CLAIMS:

Claims 1 – 29 (Cancelled)

30. (Previously Presented) An isolated nucleic acid molecule comprising a polynucleotide sequence selected from the group consisting of:

(a) an isolated polynucleotide encoding a polypeptide corresponding to amino acids 1 to 1099 of SEQ ID NO:4 including the start codon;

(b) an isolated polynucleotide encoding a polypeptide corresponding to amino acids 2 to 1099 of SEQ ID NO:4 minus the start codon;

(c) an isolated polynucleotide which represents the complimentary sequence (antisense) of (a), (b), or (c).

31. (Previously Presented) The isolated nucleic acid molecule of claim 30, wherein said polynucleotide is (a).

32. (Currently Amended) The isolated nucleic acid molecule of claim 31, wherein said polynucleotide comprises nucleotides 1 to 3297 of SEQ ID NO:[[3]]2.

33. (Previously Presented) The isolated nucleic acid molecule of claim 30, wherein said polynucleotide is (b).

34. (Currently Amended) The isolated nucleic acid molecule of claim 33, wherein said polynucleotide comprises nucleotides 4 to 3297 of SEQ ID NO:[[3]]2.

35. (Previously Presented) The isolated nucleic acid molecule of claim 30, wherein said polynucleotide is (c).

36. (Previously Presented) A recombinant vector comprising the isolated nucleic acid molecule of claim 30.

37. (Previously Presented) A recombinant host cell comprising the vector sequences of claim 36.

38. (Previously Presented) A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 37 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

39. (Previously Presented) The isolated polynucleotide of claim 30 wherein said nucleic acid sequence further comprises a heterologous nucleic acid sequence.

40. (Previously Presented) The isolated polynucleotide of claim 39 wherein said heterologous nucleic acid sequence encodes a heterologous polypeptide.

41. (Previously Presented) The isolated polynucleotide of claim 35 wherein said heterologous polypeptide is the Fc domain of an immunoglobulin.
42. (Previously Presented) An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 80.0% identical to the complete sequence provided in claim 30, wherein said polynucleotide encodes a polypeptide capable of modulating cellular development.
43. (Previously Presented) The isolated polynucleotide of claim 42 wherein said nucleic acid sequence further comprises a heterologous nucleic acid sequence.
44. (Previously Presented) The isolated polynucleotide of claim 43 wherein said heterologous nucleic acid sequence encodes a heterologous polypeptide.
45. (Previously Presented) The isolated polynucleotide of claim 44 wherein said heterologous polypeptide is the Fc domain of an immunoglobulin.
46. (Previously Presented) An isolated nucleic acid molecule that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(c) of Claim 30, wherein said stringent conditions refers to a hybridization that is at least as stringent as the following conditions: an overnight hybridization at 50 degrees C in a solution comprising 5x SSC, 0.5% SOS, 1.0 mM MEDTA, pH 8.0, followed by washing the filters in 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate, wherein said polynucleotide encodes a polypeptide capable of modulating cellular development.
47. (Previously Presented) The isolated polynucleotide of claim 50 wherein said nucleic acid sequence further comprises a heterologous nucleic acid sequence.
48. (Previously Presented) The isolated polynucleotide of claim 51 wherein said heterologous nucleic acid sequence encodes a heterologous polypeptide.
49. (Previously Presented) The isolated polynucleotide of claim 52 wherein said heterologous polypeptide is the Fc domain of an immunoglobulin.